Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Results From a Large French Observational Study ( MyCOLD Study)

作者：Kévin Chevalier, Matthieu Holub, Romain Palich, K. Blanckaert, Laurent Gilardin, Louis Terriou, Bérangère Arnould, Solal Bellaiche, Samuel Deshayes, J. Merindol, Simon Rolland, Simon Valentin, Rishma Amarsy, Sylvain Audia, Virginie Baltes, Amaury Barret, Pierre Cariou, Jessy Cattelan, Hortense Chassepot, D Chopin, Melissa Clément, Marine Coeffier, Thibault Comont, Soline de Monteynard, Charles Declerck, Pauline Durand, Mikaël Ebbo, Gaël Galli, Amélie Godot, Sarra Hamrouni, Charlotte Kaeuffer, Jean‐Emmanuel Kahn, Ludovic Lassel, S Léautez, Anne‐Lise Lecapitaine, G. Le Moal, David Luque-Paz, Martin Martinot, Natacha Mrozek, V. Pagis, Thomas Perpoint, V. Salle, Jean‐François Viallard, Clément Viguier, Matthieu Mahévas, Bertrand Godeau, Étienne Crickx, Marc Michel · 发表于：American Journal of Hematology · 年份：2025 · DOI：10.1002/ajh.70010 · 被引用次数：6 · 研究领域：Blood groups and transfusion、Blood disorders and treatments、Microbial infections and disease research

Mycoplasma pneumoniae (MP), primarily a respiratory pathogen, can cause extra-pulmonary manifestations including cold agglutinin syndrome (CAS). We conducted a national, multicenter, observational, ambispective study to describe the characteristics, risk factors, and outcomes of MP-associated CAS. Adult patients hospitalized for a MP-infection with CAS (hemolytic anemia with hemoglobin < 10 g/dL and C3 positive direct anti-globulin test) were included. Recovery was defined as hemoglobin > 10 g/dL off therapy. We also compared MP-infected patients with or without CAS. Sixty patients (51.7% of females; median age of 48.5 years) were included. CAS was diagnosed a median of 10 days after MP-infection symptoms onset. At diagnosis, the median hemoglobin level was 6.9 g/dL, and 71.7% of patients received red blood cell transfusions. Intensive care unit (ICU) admission was required in 45% of patients, and 16.7% experienced a venous thromboembolic event (VTE). Seventeen patients (28.3%) received glucocorticoids alone, while 40 (66.7%) did not receive any specific treatment for CAS. After a median follow-up of 56 (30-83) days, 90% of patients achieved recovery, while 2 patients (3.3%) died from sepsis and pulmonary embolism. Glucocorticoid use did not significantly impact the rate or timing of recovery. Compared with MP-infected patients from the MYCADO cohort study (n = 1267), CAS patients had significantly more VTE (p < 0.0001) and ICU admissions (p = 0.03). MP-associated CAS typical...